Literature DB >> 9063673

Key issues concerning fungistatic versus fungicidal drugs.

J R Graybill1, D S Burgess, T C Hardin.   

Abstract

Are there any fungicidal drugs available today? A critical issue in answering this question is that of definition. The simplest, most stringent definitions identify fungistatic drugs as those that inhibit growth, whereas fungicidal drugs kill fungal pathogens. The immunocompetent host is usually far better equipped to eliminate fungal pathogens than the immunosuppressed host. Therefore, it would be especially desirable to have a truly fungicidal drug, one that absolutely kills and fungi, as a treatment option for the immunosuppressed patient. The critical question would be whether a fungicidal drug can be delivered to the target site in a concentration high enough for a sufficient time to reduce the intralesional fungal counts to zero. By this simple definition, there are no fungicidal drugs available today. However, an accepted alternative definition is that often used by the bacteriologist: Fungicidal drugs are those that lead to a reduction of 99.9% of the initial inocula. Although this less restrictive in vitro standard is more easily met, it has serious limitations. Whether the 99.9% kill should be an acceptable standard remains uncertain. As an alternative, the minimum inhibitory concentration, though indicating static activity, has served well; perhaps it should be the only information reported for fungal susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063673     DOI: 10.1007/bf01575120

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  58 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

Review 2.  Coccidioidomycosis.

Authors:  D A Stevens
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

3.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

Review 4.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.

Authors:  M B Kurtz; C Douglas; J Marrinan; K Nollstadt; J Onishi; S Dreikorn; J Milligan; S Mandala; J Thompson; J M Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

7.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

Authors:  J M Rowe; J W Andersen; J J Mazza; J M Bennett; E Paietta; F A Hayes; D Oette; P A Cassileth; E A Stadtmauer; P H Wiernik
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

8.  Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS.

Authors:  A Vecchiarelli; C Monari; F Baldelli; D Pietrella; C Retini; C Tascini; D Francisci; F Bistoni
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

10.  In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

Authors:  K Bartizal; T Scott; G K Abruzzo; C J Gill; C Pacholok; L Lynch; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  19 in total

1.  A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis.

Authors:  Louis DiDone; Thomas Scrimale; Bonnie K Baxter; Damian J Krysan
Journal:  Nat Protoc       Date:  2010-05-27       Impact factor: 13.491

2.  Investigation of aryl isonitrile compounds with potent, broad-spectrum antifungal activity.

Authors:  Haroon Mohammad; Kwaku Kyei-Baffour; Waleed Younis; Dexter C Davis; Hassan Eldesouky; Mohamed N Seleem; Mingji Dai
Journal:  Bioorg Med Chem       Date:  2017-03-27       Impact factor: 3.641

3.  [Foot injury as a rare cause of scendosporiosis with fetal outcome].

Authors:  P H Pennekamp; O Diedrich; H Zhou; C N Kraft
Journal:  Unfallchirurg       Date:  2003-10       Impact factor: 1.000

4.  Antifungal activity of redox-active benzaldehydes that target cellular antioxidation.

Authors:  Jong H Kim; Kathleen L Chan; Noreen Mahoney; Bruce C Campbell
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-05-31       Impact factor: 3.944

5.  Targeting the oxidative stress response system of fungi with redox-potent chemosensitizing agents.

Authors:  Jong H Kim; Kathleen L Chan; Natália C G Faria; M de L Martins; Bruce C Campbell
Journal:  Front Microbiol       Date:  2012-03-16       Impact factor: 5.640

6.  Antidermatophytic Activity of Mikania micrantha Kunth: An Invasive Weed.

Authors:  Madhavankutty Jyothilakshmi; Mathew Jyothis; Mukalel Sankunni Latha
Journal:  Pharmacognosy Res       Date:  2015-06

7.  Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis.

Authors:  Anderson Messias Rodrigues; G Sybren de Hoog; Débora de Cássia Pires; Raimunda Sâmia Nogueira Brihante; José Júlio da Costa Sidrim; Marcos Fabio Gadelha; Arnaldo Lopes Colombo; Zoilo Pires de Camargo
Journal:  BMC Infect Dis       Date:  2014-04-23       Impact factor: 3.090

8.  Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles.

Authors:  Roberto Vazquez-Muñoz; Miguel Avalos-Borja; Ernestina Castro-Longoria
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

9.  Enhancement of commercial antifungal agents by Kojic Acid.

Authors:  Jong H Kim; Perng-Kuang Chang; Kathleen L Chan; Natália C G Faria; Noreen Mahoney; Young K Kim; Maria de L Martins; Bruce C Campbell
Journal:  Int J Mol Sci       Date:  2012-10-26       Impact factor: 5.923

10.  Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and cryptococcus with natural dihydroxybenzaldehydes.

Authors:  Jong H Kim; Natália C G Faria; M De L Martins; Kathleen L Chan; Bruce C Campbell
Journal:  Front Microbiol       Date:  2012-07-19       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.